Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC

NCT: NCT04340258 · ACTIVE_NOT_RECRUITING

NCT IDNCT04340258
StatusACTIVE_NOT_RECRUITING
Start Date2021-02-04
Completion2026-09-04
SponsorUniversity of Cincinnati (OTHER)
First posted
Last updated

Brief Summary

To Study Perioperative PD-1 Inhibitor and Cesium-131 Interstitial Brachytherapy in patients with locally recurrent HNSCC eligible for salvage surgery.

Frequently Asked Questions

What is Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC?

Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC is a clinical trial registered under NCT04340258. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT04340258?

The current status of NCT04340258 (Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC) is: ACTIVE_NOT_RECRUITING.

When did Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC start?

Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC started on 2021-02-04.

Related Devices

K160627Symphony Patient Transport System, Symphony Patient Trolley, Symphony Standard Transfer Surface, Symphony Portrait (Head/Neck) Transfer Surface, Symphony Brachytherapy solutionQfix

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑